Accelerator™ Drug Development 360° CDMO And CRO Solutions

Developing new therapies is inherently complex. Scientific uncertainty, evolving regulatory requirements, and operational fragmentation can slow progress. When activities are spread across multiple vendors and teams, handoffs can introduce delays, miscommunication, and avoidable risk — potentially jeopardizing the success of a development program.

Thermo Fisher Scientific addresses these challenges with Accelerator™ Drug Development, a coordinated suite of integrated solutions that brings together CDMO and CRO capabilities across clinical research, manufacturing, and clinical supply. By connecting these capabilities, the model helps align strategy and execution throughout the development lifecycle.

Designed to support programs across therapeutic areas and drug modalities, Accelerator Drug Development reduces operational complexity, strengthens continuity between development phases, and helps drive more predictable progress from preclinical development through commercialization.